Phase II evaluation of AMSA in patients with metastatic lung cancer

W. C. Nichols, R. T. Eagan, S. Frytak, J. N. Ingle, E. T. Creagan, L. K. Kvols

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Fifty-four patients with metastatic lung cancer were treated with AMSA. Patients with a performance score of 0-1, no prior chemotherapy, and normal liver function received a dose of 35 mg/m 2/day iv for 3 days every 4 weeks; patients with a performance score of 2-3, any prior chemotherapy, or abnormal liver functions received a dose of 30 mg/m 2/day on the same schedule. Among 53 evaluable patients, responses were noted in one with adenocarcinoma and in two with squamous cell carcinoma (overall response rate, 6%). We conclude that AMSA has limited activity in lung cancer when used in this schedule except perhaps in previously untreated squamous cell carcinoma. Only a limited number of patients with large cell or small cell carcinoma were treated.

Original languageEnglish (US)
Pages (from-to)1383-1385
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number12
StatePublished - Dec 1 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II evaluation of AMSA in patients with metastatic lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Nichols, W. C., Eagan, R. T., Frytak, S., Ingle, J. N., Creagan, E. T., & Kvols, L. K. (1980). Phase II evaluation of AMSA in patients with metastatic lung cancer. Cancer Treatment Reports, 64(12), 1383-1385.